# of Displayed Technologies: 20 / 155

Applied Category Filter (Click To Remove): Clinical Area


Categories

T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
  • College: OSU Wexner Medical Center
  • Inventors: Rubinstein, Mark
  • Licensing Officer: Schultz, Teri

Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
  • College: OSU Wexner Medical Center
  • Inventors:
  • Licensing Officer: Schultz, Teri

Gene Therapy Approach for Treating Neuropathy
TS-065913 — Gene therapy strategies for treating peripheral neuropathy.
Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart, and adipose tissue. It is a painful, debilitating disease, that is estimated to affect between 20 and 30 million Americans. The number of Americans affected by PN is likely muc…
  • College: College of Medicine (COM)
  • Inventors: Townsend, Kristy; Blaszkiewicz, Magdalena; Cao, Lei
  • Licensing Officer: Schultz, Teri

IDEAS: Revolutionizing Early Childhood Education with Automated Interaction Analysis
TS-065825 — The Need: In early childhood education settings, understanding children's interactions, both social and linguistic, is paramount for effective teaching and development monitoring. However, manual observation and analysis of these interactions can be time-consuming and subjective, hindering educa…
  • College: College of Education & Human Ecology
  • Inventors: Gonzalez Villasanti, Hugo "Hugo"; Justice, Laura
  • Licensing Officer: Dahlman, Jason "Jay"

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Schultz, Teri

Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
  • College: College of Medicine (COM)
  • Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
  • Licensing Officer: Schultz, Teri

Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes. The Need Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Targeted Nanobody Technology for Precise Antineoplastic Treatment
TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Palmieri, Dario; Ryan-Simkins, Michael
  • Licensing Officer: Willson, Christopher

Peptide-based inhibitor of host factor involved in HIV-1 replication
TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…
  • College: College of Arts & Sciences
  • Inventors: Musier-Forsyth, Karin; Tang, Yingke
  • Licensing Officer: Willson, Christopher

Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
  • College: College of Arts & Sciences
  • Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
  • Licensing Officer: Willson, Christopher

MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need: Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Schultz, Teri

Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
  • College: College of Medicine (COM)
  • Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
  • Licensing Officer: Schultz, Teri

Unveiling Unreported Pain: A Systematic Approach for Enhanced Patient Care
TS-064835 — The Need In healthcare, accurately assessing and managing pain is paramount for patient well-being and treatment efficacy. However, conventional methods of pain assessment rely heavily on verbal communication from patients, which poses challenges for individuals unable to express their pain verball…
  • College: College of Nursing
  • Inventors: Monroe, Todd
  • Licensing Officer: Taysavang, Panya

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Willson, Christopher

Magnetic Nanoparticles for Cancer Cell Classification
TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…
  • College: College of Arts & Sciences
  • Inventors: Schultz, Zachary; Rist, David; Skardal, Aleksander; Venere, Monica
  • Licensing Officer: Willson, Christopher

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

How Are You Feeling Today? Organizational Mental Health Indicator and Real-Time Help Application
TS-064244 — The Need: Organizations, particularly college campuses, are facing a growing challenge in addressing student mental health issues. The rising prevalence of severe psychological problems, anxiety disorders, and depression among students necessitates a proactive and effective solution. The existing ga…
  • College: College of Engineering (COE)
  • Inventors: Ezell, Jonathan; Kaufman, Michael
  • Licensing Officer: Dahlman, Jason "Jay"

CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian; Schelhorn, Jean
  • Licensing Officer: Dahlman, Jason "Jay"

Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

Show More Technologies

Loading icon